文献速递心力衰竭与心肌病

RBMS1缺失通过调节可变剪接改善心肌纤维化与心力衰竭

Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究探讨RNA结合蛋白RBMS1通过调控可变剪接在心力衰竭中的作用。在心力衰竭患者和小鼠心脏中RBMS1表达升高,且与心肌纤维化正相关;成纤维细胞特异性敲除RBMS1可减轻心肌纤维化并改善心功能。机制上RBMS1通过结合LMO7内含子19并剪除外显子20产生LMO7-Δe20异构体,激活TGF-β1通路;药物抑制RBMS1可改善心衰小鼠的心功能。

要点

  • RBMS1在心力衰竭患者心脏中表达升高并与心肌纤维化正相关。
  • 成纤维细胞敲除RBMS1可减轻心肌纤维化并改善心功能。
  • 低剂量去甲替林或反义寡核苷酸抑制RBMS1可改善心衰小鼠心功能。

核心结论

  • RBMS1通过调控LMO7可变剪接激活TGF-β1通路促进心肌纤维化,遗传或药理抑制RBMS1可改善小鼠心功能,提示其作为心力衰竭治疗靶点的潜力。

研究设计与样本

  • 在心力衰竭患者和小鼠心脏中检测RBMS1水平,并构建成纤维细胞特异性RBMS1敲除小鼠研究其在心肌纤维化和心力衰竭中的作用。
  • 采用无偏RNA测序和RNA免疫沉淀结合RNA pull-down鉴定成纤维细胞中RBMS1的下游效应分子。

主要发现

  • RBMS1表达在小鼠心肌梗死后心脏以及缺血性心肌病和肥厚型心肌病患者心脏中升高,且与心力衰竭患者心脏纤维化正相关。
  • 成纤维细胞特异性敲除RBMS1通过减轻心肌纤维化改善心功能障碍。
  • RBMS1通过结合LMO7内含子19并剪除外显子20产生LMO7-Δe20异构体,上调激活蛋白1从而激活TGF-β1通路。
  • 小鼠过表达LMO7-Δe20导致心脏纤维化和心功能障碍,TGF-β1通路抑制剂SB431542可消除该效应;SB431542还可减轻RBMS1驱动的人心脏成纤维细胞纤维化。
  • 低剂量去甲替林或反义寡核苷酸介导的RBMS1缺失可减轻心力衰竭小鼠心肌纤维化并改善心功能。

临床怎么用

  • RBMS1及其下游LMO7-Δe20-TGF-β1通路可作为心力衰竭抗纤维化治疗的潜在靶点。
  • 低剂量去甲替林或反义寡核苷酸抑制RBMS1的策略需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Previous studies have highlighted the significance of RNA-binding proteins and alternative splicing (AS) in the progression of complex diseases, but the specific involvement of AS in heart failure (HF) remains unclear. This study aimed to elucidate the role of RNA-binding motif single-stranded interacting protein 1 (RBMS1), an RNA-binding protein, in the development of HF by regulating AS and its effect on cardiac fibrosis. METHODS: The level of RBMS1 was investigated in the hearts of both HF patients and mice. Fibroblast-specific knockout RBMS1 mice were generated to investigate the role of RBMS1 in cardiac fibrosis and HF. Unbiased RNA sequencing and RNA immunoprecipitation combined with RNA pull-down were conducted to identify the downstream effector of RBMS1 in fibroblasts. RESULTS: RBMS1 expression was increased in murine hearts following myocardial infarction, as well as in the hearts of patients with ischaemic cardiomyopathy and hypertrophic cardiomyopathy. Moreover, RBMS1 levels in the hearts of HF patients were positively associated with cardiac fibrosis. Furthermore, fibroblast-specific ablation of RBMS1 improved cardiac dysfunction by mitigating myocardial fibrosis. Mechanistically, RBMS1 regulated the alternative splicing of LIM domain 7 (LMO7) by binding to intron 19 and splicing out exon 20, resulting in the formation of the LMO7-Δe20 isoform, which thus activated the transforming growth factor (TGF)-β1 pathway by upregulating activator protein 1. More importantly, overexpression of LMO7-Δe20 in mice resulted in cardiac fibrosis and cardiac dysfunction, which was ablated after treatment with TGF-β1 pathway inhibitor SB431542. In addition, SB431542 attenuated the RBMS1-driven fibrogenesis in human cardiac fibroblasts. Strikingly, pharmacologically inhibiting RBMS1 by low-dose nortriptyline or antisense oligonucleotide-mediated RBMS1 deficiency alleviated myocardial fibrosis and improved cardiac function in HF mice. CONCLUSIONS: These findings unveil a critical role of RBMS1 in regulating cardiac fibrosis through controlling the splicing of LMO7 to activate the TGF-β1 pathway. Genetic ablation or pharmacological inhibition of RBMS1 improves cardiac function in mice, suggesting its potential as a therapeutic target for HF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Li, Guo, Feng, et al. Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. Eur Heart J. 2026. PMID: 40471706. doi:10.1093/eurheartj/ehaf370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。